[Tree] Daré Bioscience's Q4 2023 earnings and updates on women's health product development

Version 0.11 (2024-04-01 20:22:09.352000)

updates: Earnings report and updates on product development

  • ➔
Version 0.1 (2024-04-01 19:22:56.261000)

updates: Surrozen advances SZN-043 into Phase 1b for liver disease

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.09 (2024-04-01 18:07:56.065000)

updates: US FDA approves cardio-renal drugs in March

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.08 (2024-03-27 00:24:01.366000)

updates: Merck's lung disease drug approval and record-high stock price

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.07 (2024-03-26 22:21:50.606000)

updates: Merck's blood pressure therapy receives FDA approval

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.06 (2024-03-26 11:27:57.624000)

updates: Nuvation Bio receives upgrade on drug prospects

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.05 (2024-03-25 12:21:34.728000)

updates: First Wave BioPharma receives neutral rating from H.C. Wainwright

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.04 (2024-03-21 00:07:26.345000)

updates: Includes updates on Harrow Health's financial results and growth prospects

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.03 (2024-03-15 00:16:02.688000)

updates: Coherus BioSciences' Q4 earnings and updates added

  • ➔
  • ➔
  • ➔
Version 0.02 (2024-02-15 02:12:11.321000)

updates: Financial updates and pipeline progress for both companies

  • ➔
  • ➔
Version 0.01 (2023-11-01 11:48:16.304000)

updates: Restructured and streamlined information

  • ➔
Version 0.0 (2023-10-31 13:04:32.172000)

updates:

  • ➔
  • ➔